Lucinda J. Billingham

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Recommendations for the use of clinical outcome assessments in rare disease drug development.

Recommendations for the use of clinical outcome assessments in rare disease drug development.

Journal: EClinicalMedicine

Published: March 05, 2026

The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial.

The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial.

Journal: Journal of leukocyte biology

Published: December 12, 2025

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Journal: Journal for immunotherapy of cancer

Published: December 01, 2025

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.

Journal: The Journal of pediatrics

Published: April 29, 2025

Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial.

Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial.

Journal: BMJ open

Published: February 26, 2025

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial.

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial.

Journal: BMC cancer

Published: January 08, 2025

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

Journal: NPJ precision oncology

Published: July 30, 2024

Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours.

Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours.

Journal: BJU international

Published: April 08, 2024

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: The Lancet. Rheumatology

Published: November 16, 2023

A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.

A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.

Journal: BMC cancer

Published: November 08, 2023

Histology independent drug development - Is this the future for cancer drugs?

Histology independent drug development - Is this the future for cancer drugs?

Journal: Cancer treatment reviews

Published: October 30, 2023

Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.

Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.

Journal: JAMA network open

Published: October 17, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026